ArticleWorld journal of hepatology2017
Hepatorenal syndrome: Update on diagnosis and therapy.
Article in World journal of hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05621005 (Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis.The Cochrane database of systematic reviews · 2019Pooled it
- The efficacy of biomarkers in the diagnosis of acute kidney injury secondary to liver cirrhosis.Medicine · 2021Trial
- Efficacy of simvastatin as adjunctive therapy in liver cirrhosis: an updated meta-analysis of randomized controlled trials.Annals of medicine and surgery (2012) · 2026Article
- Midodrine Monotherapy in Refractory Hepatorenal Syndrome-Acute Kidney Injury: A Case Report.Cureus · 2026Article
- Life after hepatorenal syndrome: unraveling quality of life, psychological distress, and treatment preferences.BMC palliative care · 2025Article
- Early Diagnosis and Timely Terlipressin in Hepatorenal Syndrome Improves Projected Outcomes and Lowers Cost.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Hepatorenal Syndrome: direct treatment costs and characteristics of patients admitted to intensive care.Einstein (Sao Paulo, Brazil) · 2025Observational
- Defining Renal Recovery in Patients With Hepatorenal Syndrome-Acute Kidney Injury: Experience From North American Studies.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Review
- Article
- Hepatorenal Syndrome-Novel Insights into Diagnostics and Treatment.International journal of molecular sciences · 2023Review
- Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.Advances in therapy · 2023Article
- The Hepatorenal Syndrome Patient Pathway: Retrospective Analysis of Electronic Health Records.Current therapeutic research, clinical and experimental · 2022Article
- Predictors of Development of Hepatorenal Syndrome in Hospitalized Cirrhotic Patients with Acute Kidney Injury.Journal of clinical medicine · 2021Article
- Liver Kidney Crosstalk: Hepatorenal Syndrome.World journal of hepatology · 2021Review
- Hepatorenal syndrome in children: a review.Pediatric nephrology (Berlin, Germany) · 2021Review
- Acute kidney injury and hepatorenal syndrome in cirrhosis.World journal of gastroenterology · 2021Review
- A Review for the Practicing Clinician: Hepatorenal Syndrome, a Form of Acute Kidney Injury, in Patients with Cirrhosis.Clinical and experimental gastroenterology · 2021Review
- Fiber scaffold bioartificial liver therapy relieves acute liver failure and extrahepatic organ injury in pigs.Theranostics · 2021Article
- Natremia and liver transplantation: The right amount of salt for a good recipe.World journal of hepatology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatorenal syndrome (HRS) is a manifestation of extreme circulatory dysfunction and entails high morbidity and mortality. A new definition has been recently recommended by the International Club of Ascites, according to which HRS diagnosis relies in serum creatinine changes instead that on a fixed high value. Moreover, new data on urinary biomarkers has been recently published. In this sense, the use of urinary neutrophil gelatinase-associated lipocalin seems useful to identify patients with acute tubular necrosis and should be employed in the diagnostic algorithm. Treatment with terlipressin and albumin is the current standard of care. Recent data show that terlipressin in intravenous continuous infusion is better tolerated than intravenous boluses and has the same efficacy. Terlipressin is effective in reversing HRS in only 40%-50% of patients. Serum bilirubin and creatinine levels along with the increase in blood pressure and the presence of systemic inflammatory response syndrome have been identified as predictors of response. Clearly, there is a need for further research in novel treatments. Other treatments have been assessed such as noradrenaline, dopamine, transjugular intrahepatic portosystemic shunt, renal and liver replacement therapy,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.